

Amphetamine salts in hepatic impairment: a case of spontaneous subdural hemorrhage

Zachary Bean, MD¹; David Cao, BS²; Shivani Kumar, MD¹; Marie Tobin, MD¹

¹Department of Psychiatry and Behavioral Neuroscience, University of Chicago; ²Pritzker School of Medicine, University of Chicago

Background

- Valproic acid (VPA), which is hepatically metabolized, is contraindicated in patients with cirrhotic disease and is associated with hyperammonemia and delirium¹.
- Mixed amphetamine salts (MAS), also hepatically metabolized, have been linked to risk of stroke, both ischemic and hemorrhagic².
- The following case presents a patient with cirrhosis who developed hyperammonemia, delirium, and spontaneous subdural hemorrhage following initiation of VPA and MAS.

Case Presentation

Ms. C was a 53 year old woman with alcoholic cirrhosis, endometriosis, bipolar disorder, and ADHD who presented with RUQ abdominal pain and emesis. She was admitted for inability to maintain PO intake.

Hospital Day 1

- Presented to ER for RUQ abdominal pain and n/v. Admitted for inability to maintain PO intake.
- Ammonia 51, INR 1.5

Hospital Day 2

- Patient noted to have waxing & waning mentation.
- Primary team started VPA 500mg QDAY and MAS 30mg BID.

Hospital Day 6

- Patient agitated & requiring nurse assistance. Lorazepam 2mg IM administered.
- Psychiatry consulted for emotional lability. Recommended to hold psychotropics and repeat ammonia.


Hospital Day 7

- Patient unresponsive & code stroke called.
- CT head showed subdural hematoma with significant midline shift.
- Emergent craniotomy and transfer to ICU.
- Ammonia 144, INR 1.6

Discussion

Hepatic impairment results in pharmacodynamic and –kinetic changes to drugs and increases risk of adverse-drug reactions (ADRs). Up to 30% of patients with cirrhosis experience ADRs⁴.

- One study demonstrated **most fatal strokes** in stimulant use to be **hemorrhagic**. No cases were associated with prescribed psychostimulants².
- A single case report exists regarding **atraumatic subdural hemorrhage** in amphetamine use³.
- Pathogenesis is posited to be vascular changes due to **metabolite-related injury or catecholamine effects**^{2,3}.



Conclusions

- This patient with **hepatic impairment** experienced a life-threatening **adverse drug effect** in the form of **spontaneous subdural hemorrhage following MAS initiation**.
- Psychiatrists should remain vigilant in considering drug metabolism in patients with historical or current hepatic impairment.



References

- (1) Lewis C, Tesar GE, Dale R. Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders. *Psychosomatics*. 2017;58(4):415-420. doi:10.1016/j.psym.2017.02.003
- (2) Darke S, Dufou J, Kaye S, Farrell M, Lappin J. Psychostimulant Use and Fatal Stroke in Young Adults. *J Forensic Sci*. 2019;64(5):1421-1426. doi:10.1111/1556-4029.14056
- (3) Nagele EP, Ross A, Then RK, Kavi T. Interhemispheric subdural and subarachnoid haemorrhage in a patient with amphetamine-induced vasculitis. *BMJ Case Reports*. Published online December 7, 2017:bcr-2017-222918. doi:10.1136/bcr-2017-222918
- (4) Weersink RA, Bouma M, Burger DM, et al. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. *Drug Saf*. 2018;41(6):603-613. doi:10.1007/s40264-017-0635-x